Semaglutide Patent Expiration: Analysis of Market Impact

Market research firm DelveInsight has released an analysis examining the potential market consequences of Semaglutide's upcoming patent expiration.

Semaglutide, a key ingredient in treatments for type 2 diabetes and obesity, currently underpins successful drugs like Novo Nordisk's Ozempic and Wegovy. The impending loss of patent protection is expected to allow generic drug manufacturers to enter the market.

The analysis by DelveInsight focuses on the shifts in market dynamics, evaluating the impact on the originator company, Novo Nordisk, and the opportunities for competing firms. It also assesses implications for treatment accessibility and cost.

DelveInsight suggests that the expiration of patent exclusivity is likely to intensify competition, potentially leading to lower prices and increased availability of Semaglutide-based therapies for patients.